Iovance Biotherapeutics (NASDAQ: IOVA) has announced the appointment of Corleen Roche as chief financial officer (CFO), effective August 6, 2025.
Ms. Roche brings three decades of biotech and life sciences industry experience to the role, including executive financial leadership in publically traded companies. Prior to joining Iovance, she served as CFO of CG Oncology, a late-stage clinical biopharmaceutical company.
Frederick G. Vogt, PhD, JD, interim CEO, president and general counsel of Iovance, commented, “I am pleased to welcome Corleen to Iovance at such an important stage in our first commercial launch. Corleen’s experience in executive financial leadership roles and multiple product launches will be invaluable as we focus on growing revenue, managing our balance sheet and advancing our mission of developing and delivering novel therapies to patients with solid tumors.”
Ms. Roche remarked, “I am excited to join Iovance to navigate our continued revenue growth and focus our pipeline investments on the highest value opportunities. I am committed to the company’s patient-focused mission while achieving our financial goals to build a profitable biotechnology company.”
